Two breakthrough vaccines are finally turning the tide against the world's deadliest childhood parasite.

Health · Published 3 October 2026 Swipe more like this →

In short: For decades, malaria defied every attempt at a vaccine due to its complex life cycle and genetic shape-shifting. Now, two WHO-approved vaccines are protecting millions of children across Africa. By layering these shots with existing tools like bed nets, health systems are achieving unprecedented success in preventing severe disease.

Malaria is a formidable adversary. Unlike viruses or bacteria that often trigger lifelong immunity after a single exposure, the malaria parasite is genetically intricate, producing thousands of potential antigens. This complexity means that natural infection provides only partial, temporary protection. Developing a vaccine required overcoming the lack of a traditional commercial market and the immense technical challenge of targeting a parasite that can persist in the human body for months without showing symptoms.

The landscape shifted on October 6, 2021, when the World Health Organization recommended the RTS,S/AS01 vaccine for widespread use. Developed through a unique public-private partnership involving GSK, PATH, and the Bill and Melinda Gates Foundation, the vaccine underwent rigorous pilot testing in Ghana, Kenya, and Malawi. By 2023, more than 6 million doses had been administered in these pilot regions, demonstrating a 13% reduction in all-cause mortality and a 30% drop in severe malaria cases. Crucially, the rollout did not discourage the use of insecticide-treated nets or other routine childhood immunizations.

In 2023, the WHO approved a second vaccine, R21/Matrix-M, expanding the available supply. While the two vaccines have not been compared against each other in a direct, side-by-side clinical trial, both are considered safe, effective, and highly cost-effective. Current guidelines recommend a four-dose schedule for children starting around five months of age, with a potential fifth dose in highly seasonal areas. As of late 2024, 17 African nations have introduced these vaccines, with millions of doses shipped to protect the most vulnerable populations.

The impact of these tools is most profound when integrated into broader health strategies. By combining vaccination with diagnostic services and preventive measures, health authorities are reaching over 90% of children in target areas with at least one form of protection. This progress marks a historic turning point in global health, offering a scalable solution to a disease that continues to claim hundreds of thousands of lives annually, particularly among children under five.

General information, not professional advice. Spotted an error? Flag the card or see corrections and complaints.

Intellect Plus is a visual educational discovery platform for exploring fascinating facts and ideas. Brain Food, Not Brain Rot. What is Intellect Plus?

Related

• A historic turning point in the fight against malaria in Africa
• Can a new vaccine finally consign malaria to the history books?
• Why has malaria persisted for over a century despite the existence of a vaccine?
• The relentless evolutionary arms race between malaria and humanity
• Why half-hearted efforts against disease lead to catastrophic failures
• Why midazolam is the medical world’s preferred tool for rapid, short-term sedation
• Why a common antidiarrheal drug is sometimes called the poor man's methadone
• Mood stabilizers are defined by their clinical effect rather than a single biological mechanism
• How local anesthetics silence your nerves to keep you awake during surgery
• Naproxen: The Versatile Painkiller That Can Also Unmask Hidden Cancerous Fevers
• Beyond Numbing: How a Common Anesthetic Rewires Biology from Humans to Plants
• Nitazoxanide is a versatile broad-spectrum drug that targets parasites, viruses, and potentially cancer cells.

More in Drugs and medication · More in Health · Latest · A–Z · All topics